Company profile

CARDINAL HEALTH INC

NYSE:CAHOther Pharmaceuticals

Drug pipeline (8)

AssetStageRevenueTrialsStatus
AMMONIA N 13approved—0—
FLUDEOXYGLUCOSE F18approved—0—
LYMPHOSEEK KITapproved—1approved
SODIUM FLUORIDE F-18approved—0—
SODIUM IODIDE I 123approved—0—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (3)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02857608phase2withdrawn2016-09-012017-08-01Cardinal Health 414, LLCA Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
NCT02509598phase2completed2015-08-012019-03-06Cardinal Health 414, LLCA Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
NCT02509585phase2terminated2016-01-012017-07-01Cardinal Health 414, LLCA Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

FDA applications (8)

ApplicationApprovedTypeApplicantProducts
ANDA 2136152025-06-12ANDACARDINAL HEALTH 414 LLC
ANDA 2036032015-11-13ANDACARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
ANDA 2037802015-07-30ANDACARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
NDA 2022072013-03-13NDACARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
ANDA 2037002013-02-25ANDACARDINAL HEALTH 414 LLC